Compare Humana Inc (HUM) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Macy's Inc — how do they compare? Humana Inc trades at $431.03 (market cap $46.49B), while Macy's Inc trades at $22.67 (market cap $5.95B). The key difference: Humana Inc is far larger — about 7.8× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 51 Days and Macy's Inc for 58 Days on average.
| HUM | M | |
|---|---|---|
Market Cap | $46.49B | $5.95B |
Volume | 2,567,704 | 6,030,644 |
Sector | Health | Consumer Cyclical |
52-Week High | $409.85 | $26.21 |
52-Week Low | $163.67 | $16.51 |
Typical Hold Time | 51 Days | 58 Days |
Enterprise Value | $53.84B | $9.75B |
Dividend Yield | 0.91% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $431.03, up 8.71% over the past day, reflecting strong momentum following a Barclays upgrade and positive earnings beats. The stock exhibits a bullish technical trend, with support at $378 and resistance at $394. Revenue has grown steadily from $92.9B in 2022 to $129.7B in 2025, though net income margins have compressed to 0.88%. Analyst consensus is a Buy with a $457.05 price target, and recent news highlights corporate initiatives and institutional investments.
The outlook for HUM is cautiously optimistic, driven by revenue growth and analyst support, but risks include margin pressure and regulatory scrutiny. Investment opportunity lies in execution of Medicare Advantage strategies, while key risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder notices.
Macy's (M) trades at $22.79 with strong valuation metrics including a P/E of 8.35 and P/S of 0.27, indicating potential undervaluation. The stock shows bullish technical signals with recent earnings beats in Q2 2026 and raised 2026 guidance. Cash flow improved to $273M in 2025, while revenue stabilized at $23.01B with net income of $582M. The company's 'Bold New Chapter' strategy is driving digital transformation and omnichannel growth.
Investment outlook appears favorable with 31.7% analyst buy ratings and $24.25 consensus price target suggesting 6.4% upside. Key risks include retail sector competition and uneven quarterly performance, but strong dividend yield and turnaround progress support total return potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
